TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03787914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Outreach Approach
Description: TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobile Outreach Approach
Description: TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
Study: NCT04273074

Intervention type: RADIATION
Group type: OTHER
Intervention: sonographic assessment
Description: preoperative sonographic assessment to airway
Study: NCT04042194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF
Description: A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of Implants and Thickening Peri-Implant Mucosa with CTG
Description: The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
Study: NCT02704598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
Study: NCT04725279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Treatment: Physiotherapy, Electrotherapy or Exercises at home
Description: The 67 patients attended the rehabilitation consultation where, after taking the anamnesis, they began to perform balance tests with a stabilometric platform and those patients with associated neck pain, with cervical motion sensors. Treatment with conventional physiotherapy, electrotherapy or exercises at home was prescribed as appropriate to each one. 3 months later, the patients were examined again in consultation, using a new anamnesis, the platform and the sensors.
Study: NCT05279391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe
Description: IV administration of Anakinra 200 mg/twice daily for 3-6 days, then 100 mg/twice daily, for up to 10 days in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: IV administration of Tocilizumab as a single dose of 8mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: IV administration of Tocilizumab as a single dose of 8mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: 4 mg per os once daily, for up to 14 days (2 mg if GFR: 30 to \<60 ml/min/1.73 m2)
Study: NCT03779438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-OHPC
Description: patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to 17-OHPC
Description: patients received weekly placebo to17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
Study: NCT05279391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dornase Alfa Inhalant Product
Description: Inh. 2,500 U/twice daily, for up to 14 days.
Study: NCT03117439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duration of antifungal therapy
Description: Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
Study: NCT04625296

Intervention type: BEHAVIORAL
Intervention: Semi-directive interview
Description: Semi-directive interview, lasting a maximum of 45 minutes

Intervention type: BEHAVIORAL
Intervention: Questionnaire : Preparedness for Caregiving Scale
Description: Preparedness for Caregiving Scale - 8 questions
Study: NCT00843778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: 200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 \[NCT00674362\], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks.
Study: NCT03591770

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINGRIX
Description: SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINGRIX
Description: SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHINGRIX
Description: SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINGRIX
Description: SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
Study: NCT02728713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial Manipulation
Description: Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham/Placebo
Description: A laying on of hands with no actual treatment being performed.
Study: NCT02165839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia (BBT-I)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating Education Learning (HEAL)
Study: NCT01055652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10mg, oral, once daily
Study: NCT02346773

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ω-3 LC-PUFA
Description: The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
Study: NCT02184455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermGEN
Description: DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
Study: NCT02718170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buried Intramedullary K-wire Fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate and Screw Fixation
Study: NCT04518995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543 matching placebo
Description: Administered as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Administered as tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTP-543
Description: Administered as tablets.
Study: NCT03610100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acelarin
Description: 825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Study: NCT00717704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: by vein once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: by mouth once daily
Study: NCT03872076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions.
Study: NCT03247452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-day Low fiber diet
Description: One-day low fiber diet before colonoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-day low fiber diet
Description: Three days low fiber diet before colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol plus ascorbic acid
Description: 2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol plus ascorbic acid
Description: 2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
Study: NCT03478293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent inject surgery
Description: Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
Study: NCT01437306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine HCl
Description: 400 mcg (2 x 200 mcg tablets) administered orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine HCl
Description: 400 mcg (2 x 200 mcg tablets) administered orally as a single dose
Study: NCT03598114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program Sustainability Action Planning Model and Training Curricula
Description: The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
Study: NCT03599375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CART cells
Description: CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv.This is a second generation CRAT.
Study: NCT00966875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Subcutaneous
Study: NCT04107454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence
Description: Active application of laser radiation on the vulvar skin. The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence
Description: Sham application of laser radiation on the vulvar skin. Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
Study: NCT01303549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B
Description: Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
Study: NCT03446248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corometrics-146 device
Description: Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
Study: NCT00966875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous
Study: NCT01206322

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal insulin
Description: The acute effects of a single 40-IU dose of intranasal insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: The acute effects of a single 40-IU dose of intranasal insulin

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The acute effects of intranasal sterile saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The acute effects of intranasal sterile saline.
Study: NCT04602234

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Description: Investigators performed lung ultrasonography on patients
Study: NCT02930174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: Application of various levels of positive pressure
Study: NCT06084975

Intervention type: PROCEDURE
Intervention: Splenic vessels preservation
Description: preservation the splenic vessels
Study: NCT03706547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/BCMA CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study: NCT03886545

Intervention type: OTHER
Intervention: Assessment of physical and functional capacities
Description: Comparaison of physical and functional capacities between caregivers with work-related musculoskeletal disorders of the shoulder healthy subjects matched in age and gender;
Study: NCT01636843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Administered subcutaneously (s.c., under the skin), once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Administered subcutaneously (s.c., under the skin), once weekly.
Study: NCT03446248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corometrics-146 device
Description: Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile phone application
Description: Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone application
Description: Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
Study: NCT00721747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Liposomal doxorubicine and Cyclophosphamide
Description: 4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
Study: NCT02138669

Intervention type: DEVICE
Group type: OTHER
Intervention: Intacs
Description: INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
Study: NCT02722980

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention consists of capsules containing placebo.
Study: NCT01636843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin), once weekly.
Study: NCT01447966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
Study: NCT02722980

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: : Probiotic capsules
Description: The intervention consists of capsules containing probiotics.